The SAFE Prospective Registry
Recruiting
N/A
Interventional Study
Atrial Fibrillation, Paroxysmal or Persistent
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 60 (estimated)
- Sponsor
- University Hospital Ostrava · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Atrial fibrillation (Afib); (paroxysmal, persistent)
* Patients indicated for catheter ablation and/or electrical cardioversion
* Signed informed consent
Exclusion Criteria:
* Longstanding or permanent atrial fibrillation
* Severe mitral regurgitation
* Heart failure with a …
Contacts